PD-L1 Expression in Lung Cancer (PELICAN)

NanoMab

Status and phase

Enrolling

Phase 2

Conditions

Non-Small Cell Lung Cancer

Treatments

Diagnostic Test: [99mTc]-NM01 SPECT/CT

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT04992715

2020-002809-26 (EudraCT Number)

PELICAN

Details and patient eligibility

About

This study will measure PD-L1 expression in metastatic NSCLC (primary tumour and metastatic lesions) using [99mTc]-NM-01 SPECT/CT and compare to PD-L1 percentage expression determined by immunohistochemistry (IHC).

Full description

A non-blinded, single centre, single interventional arm Phase II diagnostic imaging study.

Enrollment

15 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Aged 18 or above
Patients with histopathology confirmed untreated metastatic NSCLC scheduled for systemic anti-cancer therapy
ECOG status ≤ 1
Willingness and ability to comply with scheduled study visits and tests

Exclusion criteria

Pregnant or breast-feeding women
Concomitant uncontrolled medical conditions as per Investigator assessment
> 3 months between IHC PD-L1 and study recruitment
Significant abnormality of haematology (one or more of: Hb ≤ 90g/L, absolute neutrophil count (ANC) ≤1.5 x109/L, platelet count ≤75 x109/L)
Significant abnormality of renal function (defined as Cockcroft-Gault calculated creatinine clearance ≤30 mL/min)
Significant abnormality of liver function (one or more of: AST or ALT ≥2.5x ULN or ≥ 5x ULN if patient has liver metastases; total bilirubin ≥1.5xULN. In the case of patients with Gilbert's syndrome then direct bilirubin must be confirmed as ≤ ULN)
Significant cardiovascular disease, including New York Heart Association (NYHA) heart failure ≥Class III, myocardial infarction within 3 months of enrolment, unstable arrhythmia or unstable angina
History of uncontrolled allergic reactions and/or have hypersensitivity to anti-PD-L1 monoclonal antibodies, kanamycin A or aminoglycoside therapies, or other excipients that may induce hypersensitivity

Trial design

Primary purpose

Diagnostic

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

15 participants in 1 patient group

Metastatic Non-Small Cell Lung Cancer

Experimental group

Description:

Subjects with metastatic non-small cell lung cancer will be recruited as per protocol inclusion/exclusion criteria and will undergo \[99mTc\]-anti-PDL1 single-domain antibody (\[99mTc\]-NM-01) SPECT/CT imaging. \[99mTc\]-NM-01 SPECT/CT images will be compared to immunohistochemistry PD-L1 expression results.

Treatment:

Diagnostic Test: [99mTc]-NM01 SPECT/CT

Trial contacts and locations

Central trial contact

Honghoi Ting; Gary JR Cook

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms